Abstract: Slide Presentations |

Functional and marker MicroPET imaging in a murine model of orthotopic lung cancer FREE TO VIEW

James R. Bading, PhD; Ross M. Bremner, MD, PhD; Eric M. Sievers, MD*; Xiaoyuan Chen, PhD; Robert D. Bart, MD; Ryan Park, BS; Leah M. Backhus, MD
Author and Funding Information

Keck School of Medicine of the University of Southern California, Los Angeles, CA


Chest. 2004;126(4_MeetingAbstracts):748S-b-749S. doi:10.1378/chest.126.4_MeetingAbstracts.748S-b
Text Size: A A A
Published online


PURPOSE:  High resolution MicroPET technology has recently been developed. 64Cu-DOTA-PEG-E[c(RGDyK)]2 (64Cu-RGD) is a cyclic RGD peptide that has previously demonstrated specific binding to ávâ3-integrin; a cell-cell adhesion molecule implicated in angiogenesis and metastasis, and expressed in many tumors including NSCLC. We studied the feasibility of serial MicroPET imaging in an orthotopic murine model of human lung cancer utilizing 18FDG and 64Cu-RGD.

METHODS:  Human lung adenocarcinoma cells (NCI-H1975) were implanted in the left lung upper lobe, and subcutaneously to the right flank of 6 week-old SCID-bg mice (2x106cells). MicroPET images were acquired (Concorde Microsystems, Knoxville, TN) after injection of 18FDG (1,2,3,4 weeks) and 64Cu-RGD (4 weeks). Relative tracer uptake was expressed as the ratio of mean counts in tumor to reference regions. Autoradiography or necroscopy was performed at four weeks.

RESULTS:  Tumor growth and progression to mediastinal metastases were detectable using 18FDG in all mice, but mediastinal disease was masked by intense cardiac uptake. 64Cu-DOTA-RGD demonstrated specific uptake in tumor deposits with an uptake value of 7.5 as compared with 2.6 for 18FDG (Figure).

CONCLUSION:  Serial imaging of growth and progression of lung cancer in small animals is possible using MicroPET. Marker specific imaging with 64Cu-RGD provides an improved in vivo tool to study tumor biology.

CLINICAL IMPLICATIONS:  In the future, marker peptides may be coupled to chemotherapeutic or radiotherapeutic compounds, allowing cell specific delivery and dynamic imaging of therapeutic response in cancer patients.

DISCLOSURE:  E.M. Sievers, None.

Tuesday, October 26, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Cross-sectional diagnostic imaging in lung cancer.
Program in Evidence-based Care | 12/15/2006
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543